Repaglinide Accord

Country: European Union

Language: Bulgarian

Source: EMA (European Medicines Agency)

Buy It Now

Patient Information leaflet Patient Information leaflet (PIL)
21-01-2022
Summary of Product characteristics Summary of Product characteristics (SPC)
21-01-2022
Public Assessment Report Public Assessment Report (PAR)
21-07-2013

Active ingredient:

репаглинид

Available from:

Accord Healthcare S.L.U.

ATC code:

A10BX02

INN (International Name):

repaglinide

Therapeutic group:

Лекарства, използвани при диабет

Therapeutic area:

Захарен диабет тип 2

Therapeutic indications:

Repaglinide е показан при пациенти с диабет тип 2 (не-инсулинозависим диабет диабет (NIDDM)), чиято хипергликемия вече може да се контролира задоволително от диета, намаляване на телесното тегло и упражнения. Лечението трябва да се започне като допълнение към диета и физически упражнения за понижаване на кръвната захар във връзка с храненията.

Product summary:

Revision: 7

Authorization status:

упълномощен

Authorization date:

2011-12-22

Patient Information leaflet

                                60
Б. ЛИСТОВКА
61
ЛИСТОВКА: ИНФОРМАЦИЯ ЗА ПОТРЕБИТЕЛЯ
REPAGLINIDE ACCORD 0,5 MG ТАБЛЕТКИ
REPAGLINIDE ACCORD 1 MG ТАБЛЕТКИ
REPAGLINIDE ACCORD 2 MG ТАБЛЕТКИ
Репаглинид (Repaglinide)
ПРОЧЕТЕТЕ ВНИМАТЕЛНО ЦЯЛАТА ЛИСТОВКА
ПРЕДИ ДА ЗАПОЧНЕТЕ ДА ПРИЕМАТЕ ТОВА
ЛЕКАРСТВО,ТЪЙ КАТО ТЯ СЪДЪРЖА ВАЖНА ЗА
ВАС ИНФОРМАЦИЯ .
–
Запазете тази листовка. Може да се
наложи да я прочетете отново.
–
Ако имате някакви допълнителни
въпроси, попитайте Вашия лекар или
фармацевт.
–
Това лекарство е предписано
единствено и лично на Вас. Не го
преотстъпвайте на
други хора. То може да им навреди,
независимо, че признаците на тяхното
заболяване са
същите както Вашите.
–
Ако получите някакви нежелани
лекарствени реакции уведомете Вашия
лекар или
фармацевт. Това включва и всички
възможни нежелани реакции, неописани
в тази
листовка. Вижте точка 4.
КАКВО СЪДЪРЖА ТАЗИ ЛИСТОВКА:
1.
Какво представлява Repaglinide Accord и за
какво се използва
2.
Какво трябва да знаете, преди да
приемете Repaglinide Accord
3.
Как да приемате Repaglinide Accord
4.
Възможни нежелани реакции
5.
Как да съхранявате Repaglinide Accord
6.
Съдържание на опаковката и
допълнителна информация
1.
КАКВО ПРЕДСТАВЛЯВА REPAGLINIDE ACCORD И ЗА
КАКВО СЕ ИЗПОЛЗВА
Repaglinide
                                
                                Read the complete document

Summary of Product characteristics

                                1
ПРИЛОЖЕНИЕ I
КРАТКА ХАРАКТЕРИСТИКА НА ПРОДУКТА
                                
                                Read the complete document

Similar products

Active ingredient репаглинид

репаглинид

ATC code A10BX02

A10BX02

Marketed by Accord Healthcare S.L.U.

Accord Healthcare S.L.U.

INN (International Name) repaglinide

repaglinide

Documents in other languages

Patient Information leaflet Patient Information leaflet Spanish 21-01-2022
Summary of Product characteristics Summary of Product characteristics Spanish 21-01-2022
Public Assessment Report Public Assessment Report Spanish 21-07-2013
Patient Information leaflet Patient Information leaflet Czech 21-01-2022
Summary of Product characteristics Summary of Product characteristics Czech 21-01-2022
Public Assessment Report Public Assessment Report Czech 21-07-2013
Patient Information leaflet Patient Information leaflet Danish 21-01-2022
Summary of Product characteristics Summary of Product characteristics Danish 21-01-2022
Public Assessment Report Public Assessment Report Danish 21-07-2013
Patient Information leaflet Patient Information leaflet German 21-01-2022
Summary of Product characteristics Summary of Product characteristics German 21-01-2022
Public Assessment Report Public Assessment Report German 21-07-2013
Patient Information leaflet Patient Information leaflet Estonian 21-01-2022
Summary of Product characteristics Summary of Product characteristics Estonian 21-01-2022
Public Assessment Report Public Assessment Report Estonian 21-07-2013
Patient Information leaflet Patient Information leaflet Greek 21-01-2022
Summary of Product characteristics Summary of Product characteristics Greek 21-01-2022
Public Assessment Report Public Assessment Report Greek 21-07-2013
Patient Information leaflet Patient Information leaflet English 21-01-2022
Summary of Product characteristics Summary of Product characteristics English 21-01-2022
Public Assessment Report Public Assessment Report English 21-07-2013
Patient Information leaflet Patient Information leaflet French 21-01-2022
Summary of Product characteristics Summary of Product characteristics French 21-01-2022
Public Assessment Report Public Assessment Report French 21-07-2013
Patient Information leaflet Patient Information leaflet Italian 21-01-2022
Summary of Product characteristics Summary of Product characteristics Italian 21-01-2022
Public Assessment Report Public Assessment Report Italian 21-07-2013
Patient Information leaflet Patient Information leaflet Latvian 21-01-2022
Summary of Product characteristics Summary of Product characteristics Latvian 21-01-2022
Public Assessment Report Public Assessment Report Latvian 21-07-2013
Patient Information leaflet Patient Information leaflet Lithuanian 21-01-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 21-01-2022
Public Assessment Report Public Assessment Report Lithuanian 21-07-2013
Patient Information leaflet Patient Information leaflet Hungarian 21-01-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 21-01-2022
Public Assessment Report Public Assessment Report Hungarian 21-07-2013
Patient Information leaflet Patient Information leaflet Maltese 21-01-2022
Summary of Product characteristics Summary of Product characteristics Maltese 21-01-2022
Public Assessment Report Public Assessment Report Maltese 21-07-2013
Patient Information leaflet Patient Information leaflet Dutch 21-01-2022
Summary of Product characteristics Summary of Product characteristics Dutch 21-01-2022
Public Assessment Report Public Assessment Report Dutch 21-07-2013
Patient Information leaflet Patient Information leaflet Polish 21-01-2022
Summary of Product characteristics Summary of Product characteristics Polish 21-01-2022
Public Assessment Report Public Assessment Report Polish 21-07-2013
Patient Information leaflet Patient Information leaflet Portuguese 21-01-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 21-01-2022
Public Assessment Report Public Assessment Report Portuguese 21-07-2013
Patient Information leaflet Patient Information leaflet Romanian 21-01-2022
Summary of Product characteristics Summary of Product characteristics Romanian 21-01-2022
Public Assessment Report Public Assessment Report Romanian 21-07-2013
Patient Information leaflet Patient Information leaflet Slovak 21-01-2022
Summary of Product characteristics Summary of Product characteristics Slovak 21-01-2022
Public Assessment Report Public Assessment Report Slovak 21-07-2013
Patient Information leaflet Patient Information leaflet Slovenian 21-01-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 21-01-2022
Public Assessment Report Public Assessment Report Slovenian 21-07-2013
Patient Information leaflet Patient Information leaflet Finnish 21-01-2022
Summary of Product characteristics Summary of Product characteristics Finnish 21-01-2022
Public Assessment Report Public Assessment Report Finnish 21-07-2013
Patient Information leaflet Patient Information leaflet Swedish 21-01-2022
Summary of Product characteristics Summary of Product characteristics Swedish 21-01-2022
Public Assessment Report Public Assessment Report Swedish 21-07-2013
Patient Information leaflet Patient Information leaflet Norwegian 21-01-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 21-01-2022
Patient Information leaflet Patient Information leaflet Icelandic 21-01-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 21-01-2022
Patient Information leaflet Patient Information leaflet Croatian 21-01-2022
Summary of Product characteristics Summary of Product characteristics Croatian 21-01-2022

Search alerts related to this product

Alerts Repaglinide Accord репаглинид

Repaglinide Accord репаглинид

View documents history

Documents history Documents history

Repaglinide Accord